New Pharmacological Target to Treat Ischemic Mitral Regurgitation: Thinking Outside the Box.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Assessing emerging causes of mitral regurgitation: atrial functional mitral regurgitation.The Journal of international medical research · 2024
   Review
2. Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis.Circulation · 2023
   Article
3. Mitral Valve Adaptation: Can We Win the Race?Circulation. Cardiovascular imaging · 2018
   Article

Corrections and comments

• Comment on
  Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as